Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 11:8:373.
doi: 10.3389/fonc.2018.00373. eCollection 2018.

Long-Term Outcomes Following Conventionally Fractionated Stereotactic Boost for High-Grade Gliomas in Close Proximity to Critical Organs at Risk

Michael C Repka  1 , Siyuan Lei  1 , Lloyd Campbell  1 , Simeng Suy  1 , Jean-Marc Voyadzis  2 , Christopher Kalhorn  2 , Kevin McGrail  2 , Walter Jean  3 , Deepa S Subramaniam  4 , Jonathan W Lischalk  1 , Sean P Collins  1 , Brian T Collins  1
Affiliations

Long-Term Outcomes Following Conventionally Fractionated Stereotactic Boost for High-Grade Gliomas in Close Proximity to Critical Organs at Risk

Michael C Repka et al. Front Oncol. .

Abstract

Purpose/Objective: High-grade glioma is the most common primary malignant tumor of the CNS, with death often resulting from uncontrollable intracranial disease. Radiation dose may be limited by the tolerance of critical structures, such as the brainstem and optic apparatus. In this report, long-term outcomes in patients treated with conventionally fractionated stereotactic boost for tumors in close proximity to critical structures are presented. Materials/Methods: Patients eligible for inclusion in this single institution retrospective review had a pathologically confirmed high-grade glioma status post-surgical resection. Inclusion criteria required tumor location within one centimeter of a critical structure, including the optic chiasm, optic nerve, and brainstem. Radiation therapy consisted of external beam radiation followed by a conventionally fractionated stereotactic boost. Oncologic outcomes and toxicity were assessed. Results: Thirty patients eligible for study inclusion underwent resection of a high-grade glioma. The median initial adjuvant EBRT dose was 50 Gy with a median conventionally fractionated stereotactic boost of 10 Gy. All stereotactic treatments were given in 2 Gy daily fractions. Median follow-up time for the entire cohort was 38 months with a median overall survival of 45 months and 5-year overall survival of 32.5%. The median freedom from local progression was 45 months, and the 5-year freedom from local progression was 29.7%. Two cases of radiation retinopathy were identified following treatment. No patient experienced toxicity attributable to the optic chiasm, optic nerve, or brainstem and no grade 3+ radionecrosis was observed. Conclusions: Oncologic and toxicity outcomes in high-grade glioma patients with tumors in unfavorable locations treated with conventionally fractionated stereotactic boost are comparable to those reported in the literature. This treatment strategy is appropriate for those patients with resected high-grade glioma in close proximity to critical structures.

Keywords: Cyberknife; boost; fractionated; glioblastoma; high-grade glioma; stereotactic.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall survival for the entire cohort.
Figure 2
Figure 2
Overall survival stratified by histology.
Figure 3
Figure 3
Local control stratified by histology.
See this image and copyright information in PMC

References

    1. Gunderson LL, Tepper JE, Bogart JA. Clinical Radiation Oncology. Philadelphia, PA; London: Saunders; Elsevier; (2012). Available online at: http://www.clinicalkey.com/dura/browse/bookChapter/3-s2.0-C20100688262
    1. Walker MD, Alexander E, Hunt WE, MacCarty CS, Mahaley MS, Mealey J, et al. . Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. (1978) 49:333–43. - PubMed
    1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. (2005) 352:987–96. 10.1056/NEJMoa043330 - DOI - PubMed
    1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, et al. . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. (2009) 10:459–66. 10.1016/S1470-2045(09)70025-7 - DOI - PubMed
    1. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al. . Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. (2013) 31:337–43. 10.1200/JCO.2012.43.2674 - DOI - PMC - PubMed

LinkOut - more resources